Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
5.51 USD | -9.08% | +1.66% | +133.47% |
May. 10 | Top MIdday Gainers | MT |
May. 10 | Wall Street Set to Extend Gains on Thursday's Higher-Than-Expect Jobless Claims Report, Lifting US Equity Futures Pre-Bell | MT |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
Strengths
- According to sales estimates from analysts polled by Standard & Poor's, the company is among the best with regard to growth.
- The earnings growth currently anticipated by analysts for the coming years is particularly strong.
- Upward revisions of sales forecast reflect a renewed optimism among the analysts covering the stock.
- For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
- For the last 4 months, the company has been enjoying highly positive EPS revisions, which were frequently and significantly raised.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
- The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
- Historically, the company has been releasing figures that are above expectations.
Weaknesses
- The average consensus view of analysts covering the stock has deteriorated over the past four months.
- Over the past twelve months, analysts' consensus has been significantly revised downwards.
- Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
Ratings chart - Surperformance
Sector: Advanced Medical Equipment & Technology
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+133.47% | 90.32M | - | ||
-26.77% | 16.48B | A | ||
-43.46% | 2.79B | C+ | ||
+22.46% | 1.94B | - | ||
-12.32% | 1.46B | - | ||
+31.49% | 1.33B | B+ | ||
-16.15% | 966M | - | ||
+1.33% | 791M | - | ||
-31.07% | 788M | - | C- | |
-25.95% | 620M | B+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- SRTS Stock
- Ratings Sensus Healthcare, Inc.